The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Abstract
OBJECTIVES: To review the frequency with which infliximabloses its effect and dose "intensification" is required for Crohn's disease treatment. METHODS: Bibliographical searches were performed in MEDLINE, and European (ECCO) and American (DDW) Congresses. Studies evaluating loss of efficacy and requirement of infliximab dose intensification-defined either as an increase of the infliximab dose (generally from 5 mg/kg to 10 mg/kg) or as a decrease in the frequency of infusion (to as often as every 4 weeks)-in Crohn's disease patients were included. RESULTS: Sixteen studies evaluating the incidence of loss of response to infliximab in Crohn's disease patients were found. A total of 2,236 patients were included (the majority of them receiving a three-dose induction regimen at weeks 0, 2, and 6, followed by maintenance therapy every 8 weeks), providing 6,284 patient-years of follow-up. The mean percentage of patients with loss of infliximab response was 37%. However, as the follow-up time varied markedly among studies, the risk of losing response to infliximab is better expressed as the incidence of this complication per patient-year of follow-up. Therefore, the annual risk for loss of infliximab response was calculated to be 13% per patient-year. CONCLUSIONS: A variable but relevant proportion of Crohn's disease patients on long-term infliximab treatment lose response. This may be interpreted in two different but compatible ways: a positive view, highlighting that infliximab therapy is relatively durable, with the majority of patients predicted to continue infliximab treatment at least during the first year; or a negative view, interpreting that a significant proportion of Crohn's disease patients-more than 10% per patient-year of infliximab treatment-on long term will lose response and will require an increase in dose and/or decrease in infusion interval.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Hyams, J., Crandall, W., Kugathasan, S., Griffiths, A., Olson, A., Johanns, J., Liu, G., Travers, S., Heuschkel, R., Markowitz, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.003 · Cited by 877
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Maser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Farrell, R. J., Alsahli, M., Jeen, Y.-T., Falchuk, K. R., Peppercorn, M. A., & Michetti, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50145 · Cited by 550
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Lichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.048 · Cited by 417
Lichtenstein, G. R., Sbreu, M. T., Cohen, R. D., & Tremaine, W. J. (2006) · PubMed · Cited by 371
Predictors of response to infliximab in patients with Crohn's disease
Parsi, M. A., Achkar, J., Richardson, S., Katz, J., Hammel, J. P., Lashner, B. A., & Brzezinski, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.35390 · Cited by 252
Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
Lewis, J. D., Schwartz, J. S., & Lichtenstein, G. R. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70353-2 · Cited by 242
Infliximab in Crohn's Disease: First Anniversary Clinical Experience
Cohen, R. D., Tsang, J. F., & Hanauer, S. B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03363.x · Cited by 229
Review article: infliximab therapy for inflammatory bowel disease – seven years on
RUTGEERTS, P., VAN ASSCHE, G., & VERMEIRE, S. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02786.x · Cited by 227
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Clinical experience with infliximab therapy in 100 patients with Crohn's disease
Farrell, R. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02159-6 · Cited by 209
Arnott, I. D. R., McNeill, G., & Satsangi, J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01574.x · Cited by 192
Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease
Siegel, C. A., Hur, C., Korzenik, J. R., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.020 · Cited by 142
Infliximab dose intensification in Crohnʼs disease
Regueiro, M. D., Siemanowski, B., Kip, K. E., & Plevy, S. E. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20177 · Cited by 129
Sands, B. E., BLANK, M. A., Diamond, R. H., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02878.x · Cited by 121
γ-Secretase Inhibitors Enhance Taxane-Induced Mitotic Arrest and Apoptosis in Colon Cancer Cells
Akiyoshi, T., Nakamura, M., Yanai, K., Nagai, S., 和田, 純., Koga, K., Nakashima, H., Sato, N., Tanaka, M., & Katano, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.10.008 · Cited by 95
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
Candon, S., Mosca, A., Ruemmele, F. M., Goulet, O., Chatenoud, L., & Cézard, J. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.07.010 · Cited by 95
Hlavatý, T., Ferrante, M., Henckaerts, L., Pierik, M. J., Rutgeerts, P. J., & Vermeire, S. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20024 · Cited by 72
Crohn’s Disease: A Review of Current Treatment with a Focus on Biologics
Panés, J., Gomollón, F., Taxonera, C., Hinojosa, J., Clofent, J., & Nos, P. (2007) · Drugs · doi:10.2165/00003495-200767170-00005 · Cited by 70
Self-citationInfliximab dependency in pediatric Crohnʼs disease: Long-term follow-up of an unselected cohort
de Ridder, L., Rings, E. H. H. M., Damen, G. M., Kneepkens, C. M. F., Schweizer, J. J., Kokke, F., Benninga, M. A., Norbruis, O. F., Hoekstra, H. J., Gijsbers, C. F. M., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20329 · Cited by 67
Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital
Hommes, D. W., van de Heisteeg, B., van der Spek, M., Bartelsman, J. F. W. M., & van Deventer, S. J. H. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200203000-00002 · Cited by 62
(2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00001_9.x · Cited by 58
Kinney, T. P., Rawlins, M., Kozarek, R. A., France, R., & Patterson, D. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07286.x · Cited by 50
Predictors of response to infliximab in luminal Crohn's disease
Laharie, D., Salzmann, M., Boubekeur, H., Richy, F., Amouretti, M., Quinton, A., Couzigou, P., Lamouliatte, H., & Zerbib, F. (2005) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(05)80718-3 · Cited by 48
Mortimore, M., Gibson, P. R., Selby, W. S., Radford‐Smith, G. L., Florin, T. H., & THE INFLIXIMAB USER GROUP (2001) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2001.00039.x · Cited by 46
HCV, Iron, and Oxidative Stress: The New Choreography of Hepcidin
Trinder, D., Ayonrinde, O. T., & Olynyk, J. K. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.048 · Cited by 39
Implantable Gastric Electrical Stimulation: Ready for Prime Time?
Yin, J., & Chen, J. D. Z. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.068 · Cited by 27
Cited by
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
Ben-Horin, S., & Chowers, Y. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04612.x · Cited by 620
Louis, E., Mary, J., Vernier–Massouille, G., Grimaud, J., Bouhnik, Y., Laharie, D., Dupas, J., Pillant, H., Picon, L., Veyrac, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.034 · Cited by 597
Metadata
- Authors
- Gisbert, J. P., & Panés, J.
- Venue
- The American Journal of Gastroenterology
- Published
- 2009-01-27
- Volume
- 104
- Issue
- 3
- Pages
- 760-767
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2072640801
- Cited by
- 664
- References
- 39
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.